CD8A and neoplasm: Unpublished results by Joshi et al. suggest that SF2523 is an immunooncological inhibitor that hits tumor cells, increases the ratio of M1 to M2, and increases the infiltration of cytotoxic CD8+ T-cells in various tumor models.